Sign in with Google
bullish
Imugene (IMU AU): Pipeline Progresses; Capital Injection to Extend Cash Runway to Late 2025
325 Views13 Jan 2025 00:30
SUMMARY
- Imugene Ltd (IMU AU) announced dosing of the first Australian patient in the Phase 1b clinical trial of its allogeneic CAR T-cell therapy azer-cel in diffuse large B-cell lymphoma.
- Azer-Cel is one of the few allogeneic CAR T-cell therapies currently being evaluated in Australia. Azer-cel has potential revenue opportunity of $2.5B per annum.
- Imugene intends to raise A$46M through convertible bonds and warrants. Cost savings initiatives provide cash runway into late 2025. Early-stage pipeline and fund raising requirement make Imugene a risky bet.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Toyota Industries (6201 JP): After a High, Comes the Low of a Takeunder
- TIP Customized Taiwan Select High Div Index Rebal Preview: Methodology Change Leads to US$9bn Trade
- HSI, HSCEI, HSTECH, HSIII Index Rebalance: US$8.1bn of Flows Post Capping (June 2025)
- NWD (17 HK): Markets Pricing In A Bust
- CNI Semiconductor Chips Index Rebalance: One Change with Big Impact
Top Unpaywalled Insights
More »- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
- [IO Technicals 2025/22] Bearish Momentum Strengthens
- Texas Power Play: Grid Sovereignty, Bitcoin, and the Future of AI
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Imugene (IMU AU): Pipeline Progresses; Capital Injection to Extend Cash Runway to Late 202513 Jan 2025
- Imugene (IMU AU): Got US Patent for Oncolytic Virotherapy- A Crucial Step Forward for US Entry19 Jul 2023
- Imugene (IMU AU) Placement: Extended Runway for Clinical Programs Pipeline at Modest Equity Dilution18 Sep 2022
- Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong25 Aug 2022
x